{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T09:50:27Z","timestamp":1782208227031,"version":"3.54.5"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T00:00:00Z","timestamp":1778803200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T00:00:00Z","timestamp":1778803200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Bristol Myers Squibb"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1007\/s12325-026-03596-2","type":"journal-article","created":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T14:24:59Z","timestamp":1778855099000},"page":"3204-3229","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Indirect Treatment Comparisons of Lisocabtagene Maraleucel Versus Axicabtagene Ciloleucel and Tisagenlecleucel in Third-Line or Later Relapsed or Refractory Follicular Lymphoma"],"prefix":"10.1007","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7169-9275","authenticated-orcid":false,"given":"Alexander P.","family":"Boardman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Luis","family":"Reguera Ortega","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pearl","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Merav","family":"Bar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinender","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thalia","family":"Farazi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandro","family":"Mart\u00edn Garc\u00eda-Sancho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Izutsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,15]]},"reference":[{"issue":"3","key":"3596_CR1","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1002\/ajh.25696","volume":"95","author":"A Freedman","year":"2020","unstructured":"Freedman A, Jacobsen E. Follicular lymphoma: 2020 update on diagnosis and management. Am J Hematol. 2020;95(3):316\u201327.","journal-title":"Am J Hematol"},{"issue":"12","key":"3596_CR2","doi-asserted-by":"publisher","first-page":"1638","DOI":"10.1002\/ajh.26737","volume":"97","author":"E Jacobsen","year":"2022","unstructured":"Jacobsen E. Follicular lymphoma: 2023 update on diagnosis and management. Am J Hematol. 2022;97(12):1638\u201351.","journal-title":"Am J Hematol"},{"issue":"5","key":"3596_CR3","doi-asserted-by":"publisher","first-page":"e0177204","DOI":"10.1371\/journal.pone.0177204","volume":"12","author":"M Provencio","year":"2017","unstructured":"Provencio M, Sab\u00edn P, Gomez-Codina J, et al.; on behalf of GOTEL (Spanish Lymphoma Oncology Group). Impact of treatment in long-term survival patients with follicular lymphoma: a Spanish Lymphoma Oncology Group registry. PLoS One. 2017;12(5):e0177204.","journal-title":"PLoS ONE"},{"issue":"3","key":"3596_CR4","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/j.annonc.2020.11.008","volume":"32","author":"M Dreyling","year":"2021","unstructured":"Dreyling M, Ghielmini M, Rule S, et al.; on behalf of the ESMO Guidelines Committee. Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2021;32(3):298\u2013308.","journal-title":"Ann Oncol"},{"issue":"17","key":"3596_CR5","doi-asserted-by":"publisher","first-page":"2055","DOI":"10.1182\/blood-2015-11-624288","volume":"127","author":"BS Kahl","year":"2016","unstructured":"Kahl BS, Yang DT. Follicular lymphoma: evolving therapeutic strategies. Blood. 2016;127(17):2055\u201363.","journal-title":"Blood"},{"issue":"1","key":"3596_CR6","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1186\/s40164-024-00551-1","volume":"13","author":"PL Zinzani","year":"2024","unstructured":"Zinzani PL, Mu\u00f1oz J, Trotman J. Current and future therapies for follicular lymphoma. Exp Hematol Oncol. 2024;13(1):87.","journal-title":"Exp Hematol Oncol"},{"issue":"23","key":"3596_CR7","doi-asserted-by":"publisher","first-page":"2516","DOI":"10.1200\/JCO.2014.59.7534","volume":"33","author":"C Casulo","year":"2015","unstructured":"Casulo C, Byrtek M, Dawson KL, et al. Early relapse of follicular lymphoma after rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone defines patients at high risk for death: an analysis from the National LymphoCare Study. J Clin Oncol. 2015;33(23):2516\u201322.","journal-title":"J Clin Oncol"},{"issue":"11","key":"3596_CR8","doi-asserted-by":"publisher","first-page":"1684","DOI":"10.1182\/blood.2020010263","volume":"139","author":"C Casulo","year":"2022","unstructured":"Casulo C, Dixon JG, Le-Rademacher J, et al. Validation of POD24 as a robust early clinical end point of poor survival in FL from 5225 patients on 13 clinical trials. Blood. 2022;139(11):1684\u201393.","journal-title":"Blood"},{"issue":"2","key":"3596_CR9","first-page":"97","volume":"36","author":"KE Cahill","year":"2022","unstructured":"Cahill KE, Smith SM. Follicular lymphoma: a focus on current and emerging therapies. Oncology (Williston Park). 2022;36(2):97\u2013106.","journal-title":"Oncology (Williston Park)"},{"issue":"1","key":"3596_CR10","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1038\/bmt.2015.213","volume":"51","author":"E Van Den Neste","year":"2016","unstructured":"Van Den Neste E, Schmitz N, Mounier N, et al. Outcome of patients with relapsed diffuse large B-cell lymphoma who fail second-line salvage regimens in the International CORAL study. Bone Marrow Transplant. 2016;51(1):51\u20137.","journal-title":"Bone Marrow Transplant"},{"issue":"11","key":"3596_CR11","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.6004\/jnccn.2021.0054","volume":"19","author":"AD Zelenetz","year":"2021","unstructured":"Zelenetz AD, Gordon LI, Chang JE, et al. NCCN Guidelines\u00ae Insights: B-Cell Lymphomas, Version 5.2021. J Natl Compr Canc Netw. 2021;19(11):1218\u201330.","journal-title":"J Natl Compr Canc Netw"},{"issue":"3","key":"3596_CR12","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1111\/bjh.16872","volume":"191","author":"C McNamara","year":"2020","unstructured":"McNamara C, Montoto S, Eyre TA, et al. The investigation and management of follicular lymphoma. Br J Haematol. 2020;191(3):363\u201381.","journal-title":"Br J Haematol"},{"issue":"9","key":"3596_CR13","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1016\/j.jtct.2024.06.025","volume":"30","author":"M Iqbal","year":"2024","unstructured":"Iqbal M, Kumar A, Dreger P, et al. Clinical practice recommendations for hematopoietic cell transplantation and cellular therapies in follicular lymphoma: a collaborative effort on behalf of the American Society for Transplantation and Cellular Therapy and the European Society for Blood and Marrow Transplantation. Transplant Cell Ther. 2024;30(9):832\u201343.","journal-title":"Transplant Cell Ther"},{"issue":"8","key":"3596_CR14","doi-asserted-by":"publisher","first-page":"e593","DOI":"10.1016\/S2352-3026(24)00166-2","volume":"11","author":"KM Linton","year":"2024","unstructured":"Linton KM, Vitolo U, Jurczak W, et al. Epcoritamab monotherapy in patients with relapsed or refractory follicular lymphoma (EPCORE NHL-1): a phase\u00a02 cohort of a single-arm, multicentre study. Lancet Haematol. 2024;11(8):e593\u2013605.","journal-title":"Lancet Haematol"},{"issue":"7","key":"3596_CR15","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1182\/blood.2024025454","volume":"145","author":"LH Sehn","year":"2025","unstructured":"Sehn LH, Bartlett NL, Matasar MJ, et al. Long-term 3-year follow-up of mosunetuzumab in relapsed or refractory follicular lymphoma after \u22652 prior therapies. Blood. 2025;145(7):708\u201319.","journal-title":"Blood"},{"issue":"33","key":"3596_CR16","doi-asserted-by":"publisher","first-page":"5107","DOI":"10.1200\/JCO.23.00775","volume":"41","author":"PL Zinzani","year":"2023","unstructured":"Zinzani PL, Mayer J, Flowers CR, et al. ROSEWOOD: a phase\u00a0II randomized study of zanubrutinib plus obinutuzumab versus obinutuzumab monotherapy in patients with relapsed or refractory follicular lymphoma. J Clin Oncol. 2023;41(33):5107\u201317.","journal-title":"J Clin Oncol"},{"issue":"11","key":"3596_CR17","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1016\/S1470-2045(20)30441-1","volume":"21","author":"F Morschhauser","year":"2020","unstructured":"Morschhauser F, Tilly H, Chaidos A, et al. Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase\u00a02 trial. Lancet Oncol. 2020;21(11):1433\u201342.","journal-title":"Lancet Oncol"},{"key":"3596_CR18","unstructured":"BREYANZI\u00ae (lisocabtagene maraleucel) [package insert]. Bothell, WA: Juno Therapeutics Inc., a Bristol-Myers Squibb Company; February 2026."},{"key":"3596_CR19","unstructured":"BREYANZI\u00ae (lisocabtagene maraleucel) [summary of product characteristics]. Dublin, Ireland: Bristol-Myers Squibb Pharma EEIG; December 2025."},{"key":"3596_CR20","unstructured":"Bristol Myers Squibb. Bristol Myers Squibb receives approval from the European Commission to expand use of CAR T\u00a0cell therapy Breyanzi for relapsed or refractory follicular lymphoma. https:\/\/news.bms.com\/news\/details\/2025\/Bristol-Myers-Squibb-Receives-Approval-from-the-European-Commission-to-Expand-Use-of-CAR-T-Cell-Therapy-Breyanzi-for-Relapsed-or-Refractory-Follicular-Lymphoma\/default.aspx. Published March 14, 2025. Accessed April 14, 2025 [press release]."},{"issue":"8","key":"3596_CR21","doi-asserted-by":"publisher","first-page":"2199","DOI":"10.1038\/s41591-024-02986-9","volume":"30","author":"F Morschhauser","year":"2024","unstructured":"Morschhauser F, Dahiya S, Palomba ML, et al. Lisocabtagene maraleucel in follicular lymphoma: the phase\u00a02 TRANSCEND\u00a0FL study. Nat Med. 2024;30(8):2199\u2013207.","journal-title":"Nat Med"},{"key":"3596_CR22","unstructured":"YESCARTA\u00ae (axicabtagene ciloleucel) [package insert]. Santa Monica, CA: Kite Pharma, Inc.; February 2026."},{"key":"3596_CR23","unstructured":"KYMRIAH\u00ae (tisagenlecleucel) [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; December 2025."},{"key":"3596_CR24","unstructured":"KYMRIAH\u00ae (tisagenlecleucel) [summary of product characteristics]. Dublin, Ireland: Novartis Europharm Limited; June 2025."},{"key":"3596_CR25","unstructured":"YESCARTA\u00ae (axicabtagene ciloleucel) [summary of product characteristics]. Hoofddorp, The Netherlands: Kite Pharma EU B.V; December 2025."},{"issue":"1","key":"3596_CR26","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/S1470-2045(21)00591-X","volume":"23","author":"CA Jacobson","year":"2022","unstructured":"Jacobson CA, Chavez JC, Sehgal AR, et al. Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase\u00a02 trial. Lancet Oncol. 2022;23(1):91\u2013103.","journal-title":"Lancet Oncol"},{"issue":"2","key":"3596_CR27","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1038\/s41591-021-01622-0","volume":"28","author":"NH Fowler","year":"2022","unstructured":"Fowler NH, Dickinson M, Dreyling M, et al. Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase\u00a02 ELARA trial. Nat Med. 2022;28(2):325\u201332.","journal-title":"Nat Med"},{"issue":"17","key":"3596_CR28","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1182\/blood.2023021567","volume":"143","author":"M Dreyling","year":"2024","unstructured":"Dreyling M, Fowler NH, Dickinson M, et al. Durable response after tisagenlecleucel in adults with relapsed\/refractory follicular lymphoma: ELARA trial update. Blood. 2024;143(17):1713\u201325.","journal-title":"Blood"},{"issue":"3","key":"3596_CR29","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1080\/10428194.2023.2289854","volume":"65","author":"M Dickinson","year":"2024","unstructured":"Dickinson M, Martinez-Lopez J, Jousseaume E, et al. Comparative efficacy and safety of tisagenlecleucel and axicabtagene ciloleucel among adults with r\/r follicular lymphoma. Leuk Lymphoma. 2024;65(3):323\u201332.","journal-title":"Leuk Lymphoma"},{"issue":"27","key":"3596_CR30","doi-asserted-by":"publisher","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","volume":"32","author":"BD Cheson","year":"2014","unstructured":"Cheson BD, Fisher RI, Barrington SF, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014;32(27):3059\u201368.","journal-title":"J Clin Oncol"},{"issue":"6","key":"3596_CR31","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1182\/blood.2023021243","volume":"143","author":"SS Neelapu","year":"2024","unstructured":"Neelapu SS, Chavez JC, Sehgal AR, et al. Three-year follow-up analysis of axicabtagene ciloleucel in relapsed\/refractory indolent non-Hodgkin lymphoma (ZUMA-5). Blood. 2024;143(6):496\u2013506.","journal-title":"Blood"},{"issue":"S2","key":"3596_CR32","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1002\/hon.3196_LBA4","volume":"41","author":"F Morschhauser","year":"2023","unstructured":"Morschhauser F, Dahiya S, Palomba ML, et al. TRANSCEND\u00a0FL: phase\u00a02 study results of lisocabtagene maraleucel (liso-cel) in patients (pts) with relapsed\/refractory (R\/R) follicular lymphoma (FL). Hematol Oncol. 2023;41(S2):877\u201380.","journal-title":"Hematol Oncol"},{"issue":"2 suppl","key":"3596_CR33","doi-asserted-by":"publisher","first-page":"S194","DOI":"10.1016\/S2666-6367(23)00321-4","volume":"29","author":"NH Fowler","year":"2023","unstructured":"Fowler NH, Schuster SJ, Yang H, et al. Matching-adjusted indirect comparison of efficacy and safety for tisagenlecleucel and mosunetuzumab in patients (pts) with relapsed\/refractory follicular lymphoma (r\/r FL). Transplant Cell Ther. 2023;29(2 suppl):S194.","journal-title":"Transplant Cell Ther"},{"issue":"S2","key":"3596_CR34","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1002\/hon.3164_386","volume":"41","author":"MD Ray","year":"2023","unstructured":"Ray MD, Kanters S, Beygi S, et al. Matching-adjusted indirect comparisons of axi-cel to mosunetuzumab for the treatment of relapsed\/refractory follicular lymphoma. Hematol Oncol. 2023;41(S2):522\u20133.","journal-title":"Hematol Oncol"},{"issue":"25","key":"3596_CR35","doi-asserted-by":"publisher","first-page":"3083","DOI":"10.1002\/sim.3697","volume":"28","author":"PC Austin","year":"2009","unstructured":"Austin PC. Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples. Stat Med. 2009;28(25):3083\u2013107.","journal-title":"Stat Med"},{"key":"3596_CR36","unstructured":"R Core Team. R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. 2019. https:\/\/www.R-project.org\/."},{"issue":"2","key":"3596_CR37","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1177\/0272989X17725740","volume":"38","author":"DM Phillippo","year":"2018","unstructured":"Phillippo DM, Ades AE, Dias S, Palmer S, Abrams KR, Welton NJ. Methods for population-adjusted indirect comparisons in health technology appraisal. Med Decis Making. 2018;38(2):200\u201311.","journal-title":"Med Decis Making"},{"issue":"2","key":"3596_CR38","doi-asserted-by":"publisher","first-page":"S222","DOI":"10.1016\/j.jtct.2023.12.289","volume":"30","author":"Z Chahine","year":"2024","unstructured":"Chahine Z, Fields K, Amr M, et al. Bendamustine-containing regimens before CAR T-cell therapy have detrimental effect on progression-free survival. Transplant Cell Ther. 2024;30(2):S222\u20133.","journal-title":"Transplant Cell Ther"},{"issue":"2","key":"3596_CR39","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1200\/JCO.23.01097","volume":"42","author":"G Iacoboni","year":"2024","unstructured":"Iacoboni G, Navarro V, Martin-Lopez AA, et al. Recent bendamustine treatment before apheresis has a negative impact on outcomes in patients with large B-cell lymphoma receiving chimeric antigen receptor T-cell therapy. J Clin Oncol. 2024;42(2):205\u201317.","journal-title":"J Clin Oncol"},{"key":"3596_CR40","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2025-467","author":"S Ahmed","year":"2025","unstructured":"Ahmed S, Garcia-Sancho AM, Reguera JL, et al. Three-year efficacy and longitudinal safety of lisocabtagene maraleucel (liso-cel) in patients with third-line or later (3L+) follicular lymphoma (FL) from TRANSCEND\u00a0FL. Blood. 2025;146(suppl 1):467\u20138.","journal-title":"Blood"},{"issue":"1","key":"3596_CR41","doi-asserted-by":"publisher","first-page":"151758","DOI":"10.1016\/j.soncn.2024.151758","volume":"41","author":"N McEntee","year":"2025","unstructured":"McEntee N, Manago J, Lu C, Holmes L. Implementation of a lisocabtagene maraleucel chimeric antigen receptor T-cell therapy outpatient monitoring program: multicenter nursing\/advanced practice provider perspectives. Semin Oncol Nurs. 2025;41(1):151758.","journal-title":"Semin Oncol Nurs"},{"issue":"9","key":"3596_CR42","doi-asserted-by":"publisher","first-page":"2169","DOI":"10.1080\/10428194.2021.1910686","volume":"62","author":"ML Palomba","year":"2021","unstructured":"Palomba ML, Jun MP, Lymp J, et al. Postinfusion monitoring costs by site of care for patients with relapsed\/refractory large B-cell lymphoma receiving third- or later-line treatment with lisocabtagene maraleucel in the TRANSCEND NHL 001 and OUTREACH trials. Leuk Lymphoma. 2021;62(9):2169\u201376.","journal-title":"Leuk Lymphoma"},{"issue":"2 suppl","key":"3596_CR43","doi-asserted-by":"publisher","first-page":"S355","DOI":"10.1016\/j.jtct.2023.12.496","volume":"30","author":"SK Tiwana","year":"2024","unstructured":"Tiwana SK, Krimmel T, Huynh L, et al. Comparative study evaluating hospitalizations and critical care stays among patients with R\/R large B-cell lymphoma (LBCL) treated with CAR T\u00a0cell therapies lisocabtagene maraleucel (liso-cel) and axicabtagene ciloleucel (axi-cel) in the inpatient (IP) and outpatient (OP) setting using United States (US) claims data. Transplant Cell Ther. 2024;30(2 suppl):S355.","journal-title":"Transplant Cell Ther"},{"key":"3596_CR44","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/1471-2288-12-9","volume":"12","author":"P Guyot","year":"2012","unstructured":"Guyot P, Ades AE, Ouwens MJ, Welton NJ. Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves. BMC Med Res Methodol. 2012;12:9.","journal-title":"BMC Med Res Methodol"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-026-03596-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-026-03596-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-026-03596-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T09:21:18Z","timestamp":1782206478000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-026-03596-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,15]]},"references-count":44,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["3596"],"URL":"https:\/\/doi.org\/10.1007\/s12325-026-03596-2","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,15]]},"assertion":[{"value":"19 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Alexander P. Boardman received consultancy fees from Bristol Myers Squibb. Juan Luis Reguera Ortega has received consultancy fees from Kite\/Gilead, and speakers\u2019 bureau fees from Amgen, Incyte Corporation, and Kite\/Gilead. Pearl Wang is an employee of EVERSANA, which received funding from Bristol Myers Squibb to conduct the analyses. Merav Bar, Jinender Kumar, and Thalia Farazi are current employees and hold stock in Bristol Myers Squibb. Alejandro Mart\u00edn Garc\u00eda-Sancho declares consultancy fees for AbbVie, AstraZeneca, Bristol Myers Squibb, Genmab, GSK, Ideogen, Janssen, Kite\/Gilead, Lilly, Miltenyi Biotec, Regeneron, Roche, and Sobi; honoraria from AbbVie, AstraZeneca, BeOne Medicines, Bristol Myers Squibb, Ideogen, Incyte Corporation, Janssen, Kite\/Gilead, Kyowa Kirin, Lilly, Miltenyi Biotec, Regeneron, Roche, Sobi, and Takeda; travel from AbbVie, AstraZeneca, Bristol Myers Squibb, Ideogen, Janssen, Kite\/Gilead, and Roche; and service as an advisor for Bristol Myers Squibb. Koji Izutsu declares consultancy fees, research funding, and honoraria from AbbVie, AstraZeneca, Bristol Myers Squibb, Chugai, Genmab, Kyowa Kirin, Merck Sharp & Dohme, and Novartis, research funding from Bayer, Incyte Corporation, LOXO Oncology, and Regeneron; research funding and honoraria from Daiichi Sankyo, Gilead, Janssen, and Pfizer; consultancy fees and research funding from BeiGene, Otsuka, and Yakult; consultancy and honoraria from Ono Pharmaceutical, Symbio, and Takeda; consultancy fees from Carna Biosciences, Eisai, Mitsubishi, Nihon Shinyaku, and Zenyaku; and honoraria from Astellas, Eli Lilly, Meiji Seika, and Nihon Kayaku.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Studies used in this analysis were conducted in accordance with the Declaration of Helsinki and International Conference on Harmonization Good Clinical Practice guidelines. Institutional review boards at participating institutions approved the study protocols and amendments, and all participating patients provided written informed consent.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}